信必可治疗CVA的疗效及对细胞因子和小气道功能的影响

Efficacy of Symbicort in treatment of CVA patients and its effect on cytokine levels and small airway function

目的探讨信必可辅助治疗咳嗽变异性哮喘(CVA)患者的临床效果及对患者细胞因子、小气道功能的影响作用。方法选取本院呼吸内科2015年4月-2015年12月收治的98例CVA患者进行回顾性分析,其中50例患者采用常规治疗措施(常规组),48例患者加用信必可进行辅助治疗(信必可组),观察治疗效果差异。结果治疗前,信必可组和常规组的日间、夜间咳嗽症状积分、细胞因子、EOS计数、小气道功能指标差异无统计学意义(P>0.05);治疗后,信必可组患者的日间、夜间咳嗽症状积分、血清hs-CRP、IL-4、TNF-α及EOS计数显著的低于同期常规组患者(P<0.05);信必可组FEF25%、FEF50%、FEF75%测定值显著的高于同期常规组患者(P<0.05)。结论信必可辅助治疗CVA患者能够更加显著的改善患者的咳嗽情况,降低炎症反应水平,改善气道功能。

Objective To explore the effect of Symbicort in treatment of CVA patients and its effect on cytokine levels and small airway function. Methods The clinical data of 98 CAV patients from April to December 2015 were retrospectively analyzed, including 50 cases given conventional treatment （the conventional group） and 48 cases given Symbicort adjuvant therapy （the Symbicort group）. Results Before treatment, there was no significant difference in nighttime cough symptom score, cytokines, EOS count, and small airway function between the two groups （P 〉 0. 05 ）. After treatment, nighttime cough symptom score, serum hs-CRP, IL-4, TNF-ot and EOS count were significantly lower in the Symbicort group than in the conventional group （P 〈0. 05）. The levels of FEF25%, FEFS0% and FEF75% were significantly higher in the Symbicort group than in the conventional group （P 〈0. 05 ）. Conclusion Symbicort adjuvant treatment for CVA patients can improve their cough situation, reduce inflammation levels and improve airway function.